Drugs / RJMty19
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06314828 | May 2024 → May 2025 overdue | B-cell non-Hodgkin lymphoma | Guangdong Ruishun Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06340490 | May 2024 → Dec 2026 expected | systemic lupus erythematosus | Guangdong Ruishun Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RJMty19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06314828 ↗ |
| Known as | CD19-CAR-DNT cells | “RJMty19 (CD19-CAR-DNT cells)” NCT06314828 ↗1“RJMty19 (CD19-CAR-DNT cells)” NCT06340490 ↗ |
| Modality | Cell therapy | “Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR.” NCT06340490 ↗ |
| Target | CD19 | “anti-CD19 CAR” NCT06314828 ↗ |